The latest update on the ClinicalTrials.gov platform, managed by the National Institute of Health Sciences of the United States, regarding the “Safety, Tolerability, and Efficacy Study of VX-264 Treatment in Participants with Type 1 Diabetes” confirms a groundbreaking development in the treatment of the disease and also reveals significant international collaboration. It underscores a strong determination to put an end to the disease. Type 1 diabetes affects millions of people worldwide, and despite the continuously increasing trend in the prevalence of this autoimmune chronic disease globally, we are able to keep people with type 1 diabetes alive only by continuously administering insulin from outside, either through injections or insulin pumps. An integral part is the continuous investment of significant effort and the dynamic adjustments of insulin dosage for carbohydrates from food, physical activity, hormones, emotions, health status, and a variety of other factors that individuals cannot control.

For decades, scientists have been striving to close the chapter of type 1 diabetes. Despite surgically transplanted insulin-producing cells from donors being a solution for very complicated cases for over 30 years, a real cure for people with well-compensated diabetes and children remains wishful thinking. Today, this dream is closer to reality than ever before.

Among the numerous ongoing research studies focusing on early diagnosis, prevention, delaying clinical manifestation, and treatment of type 1 diabetes, studies conducted by Vertex Pharmaceuticals Incorporated are among those that hold the greatest promise. Find more here. The first person recently documented in the history of science as cured of type 1 diabetes, Brian Shelton, was also a participant in Vertex’s clinical trials. More here.

In this period, history is being written once again. The aforementioned authority has published an update on the commencement of recruitment for Vertex’s clinical trials using the experimental treatment VX-264. How does this differ from previous trials, and why are expectations and hopes so high? For the first time in history, science is ready to test the safety, tolerance, and effectiveness of insulin-producing cells created in the laboratory on humans without the need for immunosuppressants. Devices containing these cells will be implanted behind people’s abdominal muscles, where they will remain protected and invisible to the immune system.

Who are they looking for

The procedure awaits 17 participants across two different continents. Study will be conduct by 12 research centers, including 5 in the United States, 2 in Canada, and 5 in Europe.

You can check which centers are involved on my Instagram. (For more visual content, follow @type1dmaniac)

In Europe, candidates can apply in Italy, Germany, Switzerland, the Netherlands, and the United Kingdom.

Criteria

• Age 18 – 65 years, regardless of gender
• Treatment with insulin for type 1 diabetes for at least 5 years
• Regular use of continuous glucose monitoring (CGM) for at least 4 weeks before screening and willingness to use CGM during the study
• No history of islet cell, organ transplants, or cell therapy in the past
• Not suffering from severe complications related to diabetes, such as untreated advanced diabetic retinopathy, advanced diabetic nephropathy, skin ulcers, or diabetes-related amputations

Additional eligibility criteria for participating in the study will be discussed with candidates by the study physician.

In conclusion,

It’s exciting to see familiar faces (not just) from my social networks sharing this message, those who have signed up and are remaining hopeful in the coming days, certainly with great anticipation, and perhaps a bit of fear… The undeniable fact remains that such a step requires tremendous courage. To commit, however, is an immeasurable benefit for all of us who anxiously await a day without diabetes.

Equally challenging is now the task for those who will choose the most suitable candidate until only one name remains (for each of the mentioned centers). It is only at that point that they will begin, perhaps, the concluding segment of this lengthy journey, to which some have devoted nearly their entire professional lives. What lies ahead at the finish line? We’ll soon discover. Scientists project the study’s conclusion in May 2026.

Study Outcome Measures

In the clinical study protocol, outcome measures are categorized into primary and secondary. Primary measures are the most crucial for assessing the intervention/treatment effect. Secondary measures, while not as critical as the primary outcome measure for evaluating the intervention effect, are still relevant.

Primary Outcome Measures:
Part A and Part B: Safety and tolerability assessed by the number of participants with adverse events (AE) and serious adverse events (SAE) [Time Frame: From Day 1 to 24 months]
Part B and Part C: Change in maximum C-peptide during mixed meal tolerance test (MMTT) [Time Frame: From baseline to Day 90]

Secondary Outcome Measures:
Part C: Change in maximum C-peptide during MMTT [Time Frame: From baseline to 24 months]
Part C: Change in average daily insulin dose [Time Frame: From baseline to 24 months]
Part C: Proportion of participants who are insulin independent at a specific time [Time Frame: From Day 180 to Day 365]
Part C: Change in HbA1c values [Time Frame: From baseline to 24 months]

Appendix

Did not find your country, or region among the participants? It’s no secret that advanced treatment methods, as well as early detection and prevention, will only be available in countries and facilities preparing for this future. How far away it is also depends on you, your loved ones, and friends who do not have diabetes.

If you still today face challenges accessing insulin or reimbursing medical supplies necessary for everyday life with diabetes (including continuous glucose monitors and insulin pumps that communicate with them), start actively engaging beyond social networks. Your country’s representatives and leaders are the most suitable places. Inquire with politicians at both local and national levels about how your country supports research, specifically for type 1 diabetes, and what targeted measures are being taken to face the continuous rise in new cases. Without significant public pressure, it’s naive to expect the change.

One way to engage and learn more about diabetes advocacy may be through #dedoc°.